EN DE
Watch NexturnBioscience Co. Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

NexturnBioscience Co. Ltd (089140) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of NexturnBioscience Co. Ltd stock KRW 1,739, price KRW 1,796, that is 3.2% below the price, quality 26 out of 100. Rating: fairly valued. Calculated from audited financials with 4 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Industrials KR · ISIN KR7089140008

NC NexturnBioscience Co. Ltd logo Thin data Nov 15, 2026

NexturnBioscience Co. Ltd

089140 · KQ

The stock is already about fairly priced, weak company and price moving sideways: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Fair value 1,739 KRW · Fairly valued 
Price moving sideways (no uptrend) 
Expensive Growth (revenue 5y +48.7 %/yr in KRW) 
Thin margins · 9.8% net margin (TTM) 
Quality 26/100 
Negative free cash flow 
Trails peers (3/9) 
Narrow moat 19/100 · thin data
Thin data 
⚠ Dilution
Watch NexturnBioscience Co. Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

56,500 KRW 1,796 KRW Fair Value 1,739 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range 1,796 KRW – 56,500 KRW · fair‑value band 1,621 KRW – 1,838 KRW · the 1,796 KRW price screens above the 1,739 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow NexturnBioscience Co. in your weekly email

Every Wednesday you see whether NexturnBioscience Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nexturn Co.,Ltd. develops and produces CNC automatic lathe machines in Korea and internationally.

Show moreShow less

It provides CNC swiss-type automatic lathe products, high temperature display glass press equipment, and automatic line-up robots, as well as an intelligent intervention robot system based on robot 3D cardiovascular visualization technology.

The company was formerly known as KMT Incorporated and changed its name to Nexturn Co.,Ltd. in April 2004. Nexturn Co.,Ltd. was founded in 2000 and is based in Yongin, South Korea.

Stock analysis

NexturnBioscience Co. Ltd (089140) currently trades at 1,796 KRW, while our model-based Fair Value estimate is 1,739 KRW, so the stock looks roughly fairly valued today (gap 3.3%).

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 5,994 KRW per share, and 3 of the 3 models we run sit above the 1,796 KRW price.

Bear case: the Earnings-Based group reads lowest at 2,046 KRW, and 0 of the 3 models stay below the price. Data coverage for this calculation is low.

Scenario range: 1,621 KRW (bear) to 1,838 KRW (bull), the price of 1,796 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Industrials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

NexturnBioscience Co. Ltd reported revenue of 70.4B KRW in FY2025 versus 17.0B KRW in FY2021, a compound +42.7%/yr. Reported net income was −9.7B KRW in FY2025.

Key figures

Market cap 26.9B KRW (≈ $20.2M) Micro · P/S ratio 1.48 · Net margin 9.8% · Return on equity −1,091% · Return on assets (EBIT) −3.7% (5-year average) · Operating margin −16.8% · Revenue growth (YoY) +237% · EPS growth (YoY) −11.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).

What moves the price

The share trades about 40% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Industrials peers we cover trades at −33% fair-value upside, at −3%, 089140 screens cheaper than that median.

Fair Value models

Bear 1,621 KRW Fair Value 1,739 KRW Bull 1,838 KRW
Price 1,796 KRW · Downside -3.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 1,907 KRW 2,046 KRW 2,162 KRW 72
ROIC Compounder 1,907 KRW 2,046 KRW 2,162 KRW 71
EV/EBITDA n/a n/a 787.08 KRW 61
All 4 models by family
Earnings-Based
EPV 1,907 KRW 2,046 KRW 2,162 KRW 72
Multiples
EV/EBITDA n/a n/a 787.08 KRW 61
Asset-Based
NCAV (Graham) 4,473 KRW 5,994 KRW 8,947 KRW 52
Economic Profit
ROIC Compounder 1,907 KRW 2,046 KRW 2,162 KRW 71

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 93
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 28
Debt, balance sheet and risk of trouble
Investment 55
Does it invest with discipline instead of growing at any price?
Low Volatility 20
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+122.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.7%
Start year 2020 (pandemic). Over 10 years: +15.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.2% (2019) → −67.7% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 089140, get fair value alerts →

Compare NexturnBioscience Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Machinery, Tools, Heavy Vehicles, Trains & Ships · 48 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −3.2% · Below median
Profitability
Return on assets −2.8% · Bottom 25%
Net margin (12 months) 9.8% · Above median
Operating margin (12 months) −16.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 237.3% · Top 25%
Balance sheet
Debt / equity 0.05× · Above median

Valuation Multiplesvs Machinery, Tools, Heavy Vehicles, Trains & Ships median · lower = cheaper

P/B 0.20× · Cheapest 25%
P/S (12 months) 1.31× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)29 · sector 34
FUTURE (revenue growth)100 · sector 62
PAST (return on equity)0 · sector 100
HEALTH (low debt)98 · sector 99
DIVIDEND (yield)0 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Machinery, Tools, Heavy Vehicles, Trains & Ships stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Bosung Power Technology Co 006910 4,250 KRW 8,549 KRW +101% vs 089140
BHI Co 083650 36,250 KRW 42,130 KRW +16% vs 089140
VITZROCELL Co 082920 20,100 KRW 22,268 KRW +11% vs 089140
Tae Kwang Corporation 023160 21,450 KRW 14,672 KRW −32% vs 089140
Hyulim ROBOT Co 090710 4,645 KRW 3,099 KRW −33% vs 089140
Yuil Robotics Co 388720 54,200 KRW 34,084 KRW −37% vs 089140
Neo Technical System Co 085910 12,960 KRW 5,882 KRW −55% vs 089140
522275 522275 ₹4,320 ₹1,626 −62% vs 089140
SPG Co 058610 67,800 KRW 10,115 KRW −85% vs 089140
Sungho Electronics Corp 043260 25,900 KRW 3,785 KRW −85% vs 089140

Explore undervalued stocks

More undervalued Industrials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NexturnBioscience Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "NexturnBioscience Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/089140

Frequently asked questions

Is NexturnBioscience Co. Ltd (089140) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of 1,739 KRW versus a price of 1,796 KRW, about 3% lower (fairly valued).
What is the fair value of 089140?
Our model-based fair value for NexturnBioscience Co. Ltd is 1,739 KRW (as of Nov 15, 2026), built from audited fundamentals. The current price: 1,796 KRW.
What is the quality score of 089140?
NexturnBioscience Co. Ltd has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NexturnBioscience Co. Ltd (089140)?
Our model-based price target is the fair value of 1,739 KRW (as of Nov 15, 2026) from 4 valuation models. Cautious scenario 1,621 KRW, optimistic scenario 1,838 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the NexturnBioscience Co. Ltd stock forecast for 2026?
Our models put fair value at 1,739 KRW, about 3% lower versus a price of 1,796 KRW (fairly valued). Cautious scenario 1,621 KRW, optimistic scenario 1,838 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of NexturnBioscience Co. Ltd (089140)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NexturnBioscience Co. Ltd it is 1,739 KRW per share (as of Nov 15, 2026), against a price of 1,796 KRW. It is the blended result of 4 valuation models in 4 families (Earnings-Based, Multiples, Asset-Based, Economic Profit).
Is NexturnBioscience Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 089140 trades above its calculated fair value: price 1,796 KRW, fair value 1,739 KRW, a gap of about −3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 089140?
No. The price is what the market pays today (1,796 KRW); the fair value is what the company's own numbers justify (1,739 KRW). For NexturnBioscience Co. Ltd the two are 56.82 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is NexturnBioscience Co. Ltd worth?
The market values NexturnBioscience Co. Ltd at about 26.9B KRW (market capitalisation, as of Nov 15, 2026). Per share that is 1,796 KRW; our models calculate a fair value of 1,739 KRW per share.
What do the bullish and bearish scenarios say about 089140?
Our models span a range for NexturnBioscience Co. Ltd: cautious scenario 1,621 KRW, base 1,739 KRW, optimistic 1,838 KRW per share (as of Nov 15, 2026, price 1,796 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NexturnBioscience Co. Ltd (089140)?
Balance-sheet figures for NexturnBioscience Co. Ltd (as of Nov 15, 2026): debt of 0.05 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 089140 from its 52-week high?
NexturnBioscience Co. Ltd trades at 1,796 KRW, about 40% below its 52-week high of 2,995 KRW and at the low of 1,796 KRW (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of 1,739 KRW is for.
Which stocks are comparable to NexturnBioscience Co. Ltd?
From the same area (Industrials) we also value Sungho Electronics Corp, SPG Co, BHI Co, VITZROCELL Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NexturnBioscience Co. Ltd stock attractive at the current price?
The data as of Nov 15, 2026: price 1,796 KRW, calculated fair value 1,739 KRW (−3%), Quality Score 26/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 089140 calculated?
We run NexturnBioscience Co. Ltd through 4 models from 4 families: Earnings-Based, Multiples, Asset-Based, Economic Profit. Every model gets the same audited fundamentals; the fair value of 1,739 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. NexturnBioscience Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NexturnBioscience Co. Ltd (089140)?
The closing price on Nov 18, 2026 was 1,796 KRW. Our model-based fair value is 1,739 KRW, about 3% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NexturnBioscience Co. Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (1,621 KRW to 1,838 KRW), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of NexturnBioscience Co. Ltd

How large is the market capitalisation of NexturnBioscience Co. Ltd (089140)?
The market capitalisation of NexturnBioscience Co. Ltd is 26.9B KRW (≈ $20.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NexturnBioscience Co. Ltd (089140)?
The price-to-sales ratio of NexturnBioscience Co. Ltd is 1.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of NexturnBioscience Co. Ltd (089140)?
The net margin of NexturnBioscience Co. Ltd is 9.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NexturnBioscience Co. Ltd (089140)?
The return on equity (ROE) of NexturnBioscience Co. Ltd is −1,091% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NexturnBioscience Co. Ltd (089140)?
On an EBIT basis the return on assets of NexturnBioscience Co. Ltd is −3.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NexturnBioscience Co. Ltd (089140)?
The operating margin of NexturnBioscience Co. Ltd is −16.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NexturnBioscience Co. Ltd (089140)?
Revenue at NexturnBioscience Co. Ltd is growing 237% versus a year earlier (3y avg +44.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at NexturnBioscience Co. Ltd (089140)?
Earnings per share at NexturnBioscience Co. Ltd are down 11.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does NexturnBioscience Co. Ltd (089140) generate?
The free cash flow of NexturnBioscience Co. Ltd is −6.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does NexturnBioscience Co. Ltd (089140) carry?
The net debt of NexturnBioscience Co. Ltd is 74.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch NexturnBioscience Co. Ltd in the live analysis

One click puts NexturnBioscience Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.